Bristol-Myers Squibb to buy Inhibitex for $2.5 billion
Pharmaceutical giant Bristol-Myers Squibb Company announced it was acquiring Inhibitex, Inc., a company specializing in treatment of hepatitis C, for $2.5 billion (1.9 billion euros).
Jan 8, 2012
0
0